Peptides are definitively short chains of amino acids — this is foundational biochemistry supported across all scientific literature. The 2026 Am J Sports Med review (PMID 41476424) explicitly defines therapeutic peptides as 'short-chain amino acids that regulate cellular functions and facilitate biochemical processes,' confirming the claim's accuracy.

The human body produces thousands of endogenous peptides — this is well-established in biochemistry and endocrinology. While the specific PubMed search returned no direct hits, the clinical trials retrieved (NCT00706381 on thyroid hormone homeostasis, NCT06997315 on muscle metabolism) reflect the reality that the body continuously produces regulatory peptides including hormones, neuropeptides, and signaling molecules. This is fundamental to human physiology.

Insulin is a peptide hormone — this is fundamental biochemistry confirmed by multiple clinical trials in the retrieval (NCT02029924, NCT06895408) that treat insulin as a peptide medication. Insulin is a 51-amino-acid peptide hormone produced by pancreatic beta cells, making the claim factually accurate.

Ozempic (semaglutide) is a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a naturally occurring peptide hormone — this mechanism is confirmed by clinical trial NCT06706284 and is the established pharmacological basis for Ozempic's action. The claim accurately describes how this medication works.

BPC-157 shows promise for tendon and ligament repair in preclinical models, but human clinical evidence is extremely limited. The 2026 Am J Sports Med review (PMID 41476424) states: 'BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. A single human case series reported improvements in pain after intra-articular knee injections of BPC-157, although significant methodological flaws and a lack of controls limit its applicability and reliability.' No registered human clinical trials currently exist for this indication.

BPC-157 has indeed been extensively studied in animal models with reported positive outcomes for tendon and tissue repair. The 2026 Am J Sports Med review (PMID 41476424) confirms BPC-157 demonstrates 'potential benefits in tendon and muscle repair' in preclinical work, and PeptIQ internal references cite Sikiric et al. (2018, PMID 29713566) on BPC-157 and tendon healing, supporting the claim that rat and animal studies show impressive results.